Drugs / Convidecia
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04952727 | Aug → Nov 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04833101 Background | Apr → Sep 2021 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Press releases naming this drug 12 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Convidecia | “We aimed to assess the immunogenicity and safety of a heterologous immunisation with an adenovirus type 5-vectored vaccine (Ad5-nCOV, Convidecia) among elderly who were primed...” PMID 37360864 ↗ Jun 20231“with a recombinant adenovirus type-5-vectored Coronavirus Disease 2019 (COVID-19) vaccine (Convidecia, hereafter referred to as CV) and a protein-subunit-based COVID-19 vaccine...” PMID 35617368 ↗ May 2022 |